Susan Branford

发表

NGS in CML - New standard diagnostic procedure?

Susan Branford, Naranie Shanmuganathan, S. Branford, 2019, HemaSphere.

A comparative analysis of algorithms for somatic SNV detection in cancer

R. Daniel Kortschak, David L. Adelson, Andreas W. Schreiber, 2013, Bioinform..

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

Helen E White, Dong-Wook Kim, Timothy Hughes, 2013, Clinical chemistry.

BAM-matcher: a tool for rapid NGS sample matching

Andreas W. Schreiber, Susan Branford, Wendy T. Parker, 2016, Bioinform..

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

Deborah L White, Susan Branford, D. White, 2015, Blood.

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Susan Branford, Richard Herrmann, R. Herrmann, 2003, Blood.

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

Susan Branford, J. Reynolds, N. Briggs, 2013, Blood.

Molecular monitoring of chronic myeloid leukemia.

Susan Branford, Tim Hughes, 2003, Seminars in hematology.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Deborah L White, Simon Durrant, Susan Branford, 2008, Blood.

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib

Franziska Michor, Mithat Gonen, Susan Branford, 2014, Haematologica.

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Hans Bitter, Franco Lombardo, Joseph Schoepfer, 2017, Nature.

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.

Franziska Michor, Mithat Gonen, Susan Branford, 2011, Blood.

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Susan Branford, Ricardo Pasquini, Fabrizio Pane, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Susan Branford, Andreas Hochhaus, Jaspal Kaeda, 2003, The New England journal of medicine.

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study

Susan Branford, Timothy P. Hughes, Fabrizio Pane, 2014, International Journal of Hematology.

BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment

Susan Branford, Andrew M. Stein, Dean Bottino, 2011, Clinical Cancer Research.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Simona Soverini, Giovanni Martinelli, Susan Branford, 2006, Blood.

Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Francisco Cervantes, Susan Branford, Andreas Hochhaus, 2017, The New England journal of medicine.

Dynamics of chronic myeloid leukaemia

Martin A. Nowak, Yoh Iwasa, Franziska Michor, 2005, Nature.